Cabaletta Bio Inc (CABA)

05:46 AM

Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN

05:46 AM

04:18 AM

Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World

04:18 AM

02:27 AM

FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World

02:27 AM

Apr 03, 2025

Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat

Apr 03, 2025

Apr 03, 2025

Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com

Apr 03, 2025

Apr 03, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World

Apr 03, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat

Apr 02, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World

Apr 02, 2025

Apr 02, 2025

Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks

Apr 02, 2025

Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks

Apr 01, 2025

Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com

Apr 01, 2025

Apr 01, 2025

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener

Apr 01, 2025

Apr 01, 2025

Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks

Apr 01, 2025

Apr 01, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada

Apr 01, 2025

Mar 31, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India

Mar 31, 2025

Mar 31, 2025

BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio, Inc. SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan

Mar 31, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Mar 29, 2025

Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia

Mar 26, 2025

Mar 24, 2025

Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register

Mar 24, 2025

Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025

Mar 22, 2025

Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat

Mar 22, 2025

Mar 20, 2025

Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News

Mar 20, 2025

Mar 19, 2025

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire

Mar 19, 2025

Mar 19, 2025

Major Breakthrough: Cellares Successfully Automates Multi-Batch CAR T Production for 260,000 Patients - Stock Titan

Mar 19, 2025

Mar 17, 2025

Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView

Mar 17, 2025

Mar 16, 2025

Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat

Mar 16, 2025

Mar 16, 2025

Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat

Mar 16, 2025

Mar 12, 2025

Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat

Mar 12, 2025

Mar 09, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 09, 2025

Mar 06, 2025

Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 06, 2025